江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2014年
9期
807-809
,共3页
刘素勤%谢爱宏%谭辉%谭笑笑%李婧%黄华国
劉素勤%謝愛宏%譚輝%譚笑笑%李婧%黃華國
류소근%사애굉%담휘%담소소%리청%황화국
拉坦前列素%噻吗洛尔%原发性开角型青光眼%眼压
拉坦前列素%噻嗎洛爾%原髮性開角型青光眼%眼壓
랍탄전렬소%새마락이%원발성개각형청광안%안압
Latanoprost%Timolol%Primary open angle glaucoma%Intraocular pressure
目的：评价0.005%拉坦前列素滴眼液+0.5%噻吗洛尔滴眼液治疗原发性开角形青光眼患者的替代降眼压作用及其安全性。方法应用0.005%拉坦前列素滴眼液单一治疗的原发性开角型青光眼患者31例，给予0.005%拉坦前列素滴眼液+0.5%噻吗洛尔滴眼液替代治疗。每晚点药1次，每次1滴。将连续点药后4、8、12周的眼压与基线眼压进行比较研究，同时观察血压、心率等全身及局部不良反应。结果0.005%拉坦前列素滴眼液+0.5%噻吗洛尔滴眼液可以更有效降低眼压。连续点药4、8、12周后，与基线相比，眼压分别额外下降（2.2±1.1）mmHg、（2.0±0.9）mmHg、（2.2±1.0）mmHg，差异均具有统计学意义（P<0.05）。连续点药4、8、12周后，获得至少2mmHg眼压下降值的患者百分率分别为64.5%、61.3%、64.5%。心动过缓（3.2%）是最严重的不良反应。结论0.005%拉坦前列素+0.5%噻吗洛尔复方滴眼液能够更加有效的降低目标眼压，可以作为0.005%拉坦前列素滴眼液的替代治疗手段。
目的：評價0.005%拉坦前列素滴眼液+0.5%噻嗎洛爾滴眼液治療原髮性開角形青光眼患者的替代降眼壓作用及其安全性。方法應用0.005%拉坦前列素滴眼液單一治療的原髮性開角型青光眼患者31例，給予0.005%拉坦前列素滴眼液+0.5%噻嗎洛爾滴眼液替代治療。每晚點藥1次，每次1滴。將連續點藥後4、8、12週的眼壓與基線眼壓進行比較研究，同時觀察血壓、心率等全身及跼部不良反應。結果0.005%拉坦前列素滴眼液+0.5%噻嗎洛爾滴眼液可以更有效降低眼壓。連續點藥4、8、12週後，與基線相比，眼壓分彆額外下降（2.2±1.1）mmHg、（2.0±0.9）mmHg、（2.2±1.0）mmHg，差異均具有統計學意義（P<0.05）。連續點藥4、8、12週後，穫得至少2mmHg眼壓下降值的患者百分率分彆為64.5%、61.3%、64.5%。心動過緩（3.2%）是最嚴重的不良反應。結論0.005%拉坦前列素+0.5%噻嗎洛爾複方滴眼液能夠更加有效的降低目標眼壓，可以作為0.005%拉坦前列素滴眼液的替代治療手段。
목적：평개0.005%랍탄전렬소적안액+0.5%새마락이적안액치료원발성개각형청광안환자적체대강안압작용급기안전성。방법응용0.005%랍탄전렬소적안액단일치료적원발성개각형청광안환자31례，급여0.005%랍탄전렬소적안액+0.5%새마락이적안액체대치료。매만점약1차，매차1적。장련속점약후4、8、12주적안압여기선안압진행비교연구，동시관찰혈압、심솔등전신급국부불량반응。결과0.005%랍탄전렬소적안액+0.5%새마락이적안액가이경유효강저안압。련속점약4、8、12주후，여기선상비，안압분별액외하강（2.2±1.1）mmHg、（2.0±0.9）mmHg、（2.2±1.0）mmHg，차이균구유통계학의의（P<0.05）。련속점약4、8、12주후，획득지소2mmHg안압하강치적환자백분솔분별위64.5%、61.3%、64.5%。심동과완（3.2%）시최엄중적불량반응。결론0.005%랍탄전렬소+0.5%새마락이복방적안액능구경가유효적강저목표안압，가이작위0.005%랍탄전렬소적안액적체대치료수단。
Objective To evaluate the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops switching from latanoprost 0.005% monotherapy. Methods Thirty-one patients patients diagnosed with primary open-angle glaucoma who had an insufficient intraocular pressure (IOP) decrease with latanoprost 0.005%eyedrop monotherapy were enrolled. The latanoprost 0.005%eyedrops were discontinued,and administration of latanoprost 0.005%+ timolol maleate 0.5% fixed combination eyedrops was initiated without any washout period. IOP was compared before and at weeks 4,8,and 12 after the switch. The incidence of adverse reactions was investigated at every follow-up visit. Results At 4,8, and 12 weeks after the switch,the mean reduction in IOP from baseline were 2.2±1.1mmHg,2.0±0.9mmHg,2.2±1.1mmHg respec-tively (P<0.05). At 4,8,and 12 weeks after the switch,the percentage of patients achieving ≥2mmHg reductions in IOP were 64. 5%,61.3%,64.5%. Bradycardia caused by fixed combination eyedrops was found in one (3.2%) patinet. Conclusion When la-tanoprost 0.005% eyedrop monotherapy was replaced by latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops , IOP decreased significantly.
